Medical imaging manufacturers and professional societies joined Eli Lilly & Co. in criticizing CMS’ proposed national coverage determination (NCD)
for beta-amyloid positron emission tomography (PET) in dementia and neurodegenerative disease as too restrictive and not compatible with the current appropriate-use criteria developed by professional societies.